Pramlintide dosage and evidence
Written by Aaron CuhaReviewed Sep 2026
The short answer
Pramlintide is the only amylin drug ever approved for diabetes. The FDA now lists every Symlin product as discontinued. Approved is not the same as available.
Evidence grade for Pramlintide: Moderate. The rule: at least one finished study in people, and at least 100 people who took it. The sum on this page: 3 completed trials, 684 people given it. A grade counts how much has been done to people, not whether it works.
- People given it
- 684
- Human studies
- 3
- Found nothing
- 0
Dose
Approved label amounts
15, 30, 45, 60 and 120 mcg
The approved pramlintide amounts, in mcg.
No first-hand reports gathered yet. That is a gap in what we have collected, not a finding that nothing has been reported.
Goal pages: Fat loss and metabolism
In plain English
In plain English, from Aaron
This is how I would explain it to a friend. The evidence, with the numbers, is further down the page.
Pramlintide is a shot that copies amylin. Amylin is a hormone your pancreas releases along with insulin. It was sold as Symlin for people with diabetes who take insulin at meals. It slows your stomach and helps you feel full. It also holds back a hormone that raises blood sugar. The FDA now lists every Symlin product as discontinued. So it was approved, but you may not be able to get it.
What people take it for
- Better blood sugar for people with diabetes who take insulin at meals.
- Losing a little weight instead of gaining it on insulin.
- Needing less mealtime insulin.
What studies in people showed
In 480 people with type 1 diabetes, average blood sugar fell 0.67 points at three months. On a dummy shot it fell 0.16. They lost weight instead of gaining it. Bad low blood sugar did not become more common in that study. Two long studies of people with type 2 diabetes on insulin were pooled. At six months, blood sugar was 0.41 points lower than on the dummy. Weight was 1.8 kg lower, and they needed less insulin. In 204 people with obesity and no diabetes, it took off 3.6 kg more than a dummy shot over four months. That is about 3.7 percent of body weight. The label warns that with insulin it can drop blood sugar dangerously low. Doctors are told to cut mealtime insulin in half when starting.
What people report
Reports, not study results
The good
- Blood sugar came down a little in people already on insulin.
- Weight went down instead of up.
The bad
- Used with insulin, it can drop blood sugar dangerously low. That is why the label carries the FDA's strongest warning.
- It is one more daily shot on top of insulin, for a modest drop in blood sugar.
- Every Symlin product is now listed as discontinued, so getting it may not be possible.
Where these come from: The results and the low blood sugar warning are from the studies and the FDA label on this page. The discontinued status is from the FDA drug database. We have not collected user reports on this one yet.
My bottom line
In my opinion this is a diabetes tool, not a weight loss tool. It helps blood sugar a little for people on mealtime insulin, and the low blood sugar risk is serious. If you are on insulin and curious, that is a talk with your doctor, not a forum.
An opinion, not a finding. I am a coach, not a doctor.
What it has been measured to do
Measured in people
Goals Pramlintide has been tested for in people, biggest studies first. We count only what the studies on this page say, so the real numbers may be higher.
- Losing weight684 people · 2 studies
- Blood sugar and insulin480 people · 3 studies
- Feeling less hungry204 people · 1 study
33 of the 36 indexed goals have no study of any kind behind Pramlintide
No study in people, animals or cells on this page reports a result for these. That does not prove Pramlintide does nothing for them. It does mean anything you have heard about Pramlintide and one of these did not come from a study cited here.
Show full evidence
What is Pramlintide?
Pramlintide is the only amylin drug ever approved for diabetes. The FDA now lists every Symlin product as discontinued. Approved is not the same as available.
Pramlintide is a lab-made copy of amylin, a hormone the pancreas releases along with insulin. It was approved as Symlin, taken with mealtime insulin, for type 1 and type 2 diabetes. As of September 2026, the FDA's drug database lists every Symlin product as discontinued. We checked that with the regulator directly, not by guessing from whether it is on shelves. It slows how fast the stomach empties, holds back glucagon and turns down appetite.
In a 52-week study of 480 people with type 1 diabetes, it lowered average blood sugar (HbA1c) by 0.67 points at week 13, against 0.16 on a dummy shot. People lost weight instead of gaining it. Its label carries the FDA's strongest warning, for severe low blood sugar caused by insulin. In 204 people with obesity who were not on insulin, a mid-sized study found 3.7% more weight loss than on the dummy shot. That result later helped shape cagrilintide.
How does Pramlintide work?
It switches on amylin receptors. That slows how fast the stomach empties, holds back glucagon after meals and helps people feel full. It works alongside insulin.
The evidence, in charts
Fig. 1a · how many people
684people, across 2 studies in people cited here
| Study | People | Share |
|---|---|---|
| Diabetes Care 2002 | 480 | 70% |
| Journal of Clinical Endocrinology and Metabolism 2007 | 204 | 30% |
One study holds 70% of these people, so the total rests more on one study than its size suggests. Counts are the number of people each study on this page says it signed up. That includes studies that only watched people and gave nobody the compound. 2 more studies in people give no headcount and are not counted here. Studies still signing people up are left out, and only studies cited on this page are counted.
Fig. 1b · evidence mix
All 4 sources here are studies in people.
- Study in people · done in people4100%
Counted from the list of sources on this page. It counts only what we cite, so there may be more studies out there. A review counts once, however many studies it sums up.
Fig. 2 · evidence over time
The studies cover 4 different years, 2002 to 2015, counted from the list of sources on this page. The newest source on file is from 2015, more than five years ago. Research on it may have gone quiet.
Fig. 3 · legal status at a glance
US
Approved
UK
Approved
AU
Approved
CA
Approved
Approved in all four countries shown. This is what the law says, not a verdict on the science. See Legal status below for the full text and any notes.
Fig. 5 · what the molecule is
- Kind of compound
- Peptide
- Molecule weight
- 3,949.4 Da
- Half-life
- About 48 minutesUltra-short, minutes
- Chain length
- None on file
No amino acid sequence is on file for Pramlintide, so none is drawn rather than guessed from a name.
The studies we cite
- Study in people2002A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes
Pramlintide improved blood sugar control in type 1 diabetes, and people lost weight instead of gaining it. Four hundred and eighty patients were treated alongside their insulin for a year. At three months, average blood sugar had fallen by 0.67 percentage points on the drug and 0.16 on a dummy injection. Severe low blood sugar episodes did not become more frequent. The improvement is real but modest, and it is a blood number rather than a count of complications avoided.
52-week trial in 480 patients with type 1 diabetes: pramlintide lowered HbA1c by 0.67% versus 0.16% for placebo at week 13, with weight loss rather than gain and no rise in severe hypoglycemia.
- Study in people2004Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients
In type 2 diabetes the benefit is real but small. Researchers pooled two long trials of overweight and obese patients who were already on insulin. After six months, the drug groups had about 0.41 percentage points lower average blood sugar than the dummy groups, and were 1.8 kg lighter. They also needed less insulin. Pooling two finished trials is not the same as running a new one, and 1.8 kg over six months is a modest return for a daily injection.
Pooled analysis of two long-term trials: placebo-corrected reductions of 0.41% in HbA1c and 1.8 kg in weight at 26 weeks, with lower insulin use.
- Study in people2007Progressive reduction in body weight after treatment with the amylin analog pramlintide in obese subjects: a phase 2, randomized, placebo-controlled, dose-escalation study
In people with obesity but no diabetes, pramlintide produced a small amount of weight loss. Two hundred and four of them took it or a dummy injection for four months, with the dose built up slowly. The drug group ended 3.6 kg lighter than the dummy group, about 3.7% of body weight. That is far less than newer weight drugs deliver. Its value is that it showed the amylin pathway affects appetite at all, which is the idea later drugs were built on.
16 weeks in 204 obese subjects without insulin: placebo-corrected weight loss of 3.7% (3.6 kg), showing the amylin pathway's appetite effect that later informed cagrilintide.
- Study in people2015Symlin (pramlintide acetate) injection: prescribing information
This is the regulator's instruction sheet, not a study. It approves pramlintide only as an add on to insulin taken at meals, in both type 1 and type 2 diabetes. It carries the strongest warning the regulator issues, because combining it with insulin can drop blood sugar dangerously low. To manage that, the label tells doctors to halve the mealtime insulin dose when starting. It is not approved as a weight loss drug, and it is not meant to be used alone.
FDA-approved label: adjunct to mealtime insulin in type 1 and type 2 diabetes; boxed warning for severe insulin-induced hypoglycemia and a 50% mealtime insulin reduction at initiation.
Where to buy Pramlintide
Pramlintide is an approved medicine. The approved product comes from a pharmacy, with a prescription. The vials below are sold “for research” and are not the approved drug.
No seller we track lists Pramlintide yet. We read sellers’ public product lists every week, and this section fills in as soon as one does. Every seller, graded
Common questions
Has Pramlintide been tested in people?
Yes. 684 people given it across 3 completed trials cited here, 0 of which found nothing. Pramlintide is the only amylin drug ever approved for diabetes. The FDA now lists every Symlin product as discontinued. Approved is not the same as available.
What is the Pramlintide dosage?
Approved label amounts. 15, 30, 45, 60 and 120 mcg The approved pramlintide amounts, in mcg.
Is Pramlintide FDA-approved?
Approved as Symlin. But as of September 2026, the FDA's drug database (Drugs@FDA) lists every Symlin product as discontinued. Approved does not mean still on sale.
How does pramlintide relate to cagrilintide?
Both work on amylin receptors. Pramlintide is a short-acting approved add-on to insulin. Cagrilintide is a long-acting, once a week amylin drug still being tested for obesity.
Latest reading on Pramlintide
Blog posts about Pramlintide, newest first.